Oliver Luxxe Assets’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Oliver Luxxe Assets’s Portfolio XPH Stock Details XPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-5,820	Closed	-$218K	–	129
2020 Q1	$218K	Buy	5,820 +231	+4%	+$9.84K	0.14%	109
2019 Q4	$255K	Sell	5,589 -1,309	-19%	-$51.9K	0.13%	111
2019 Q3	$244K	Buy	6,898 +460	+7%	+$17.1K	0.14%	106
2019 Q2	$252K	Buy	6,438 +19	+0.3%	+$747	0.14%	108
2019 Q1	$267K	Buy	6,419 +306	+5%	+$12.4K	0.15%	102
2018 Q4	$224K	Buy	6,113 +886	+17%	+$37.8K	0.15%	94
2018 Q3	$240K	Buy	+5,227	New	+$248K	0.14%	93
2018 Q1	–	Sell	-23,935	Closed	-$1.04M	–	103
2017 Q4	$1.04M	Buy	23,935 +1,280	+6%	+$54.4K	0.63%	46
2017 Q3	$964K	Buy	+22,655	New	+$961K	0.61%	47

Other funds holding XPH

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.99B AUM 30.41% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

FMP

Financial Management Professionals Austin, Texas $1.05B AUM 21.07% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

HCIA

Hochman Cole Investment Advisors Deerfield, Illinois $255M AUM 23.27% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Oliver Luxxe Assets's XPH Position: Q2 2020 in Review

Oliver Luxxe Assets sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q2 2020, closing a stake of 5,820 shares — an estimated $218K sold.

Oliver Luxxe Assets first reported a position in XPH in Q3 2017 and held it in 9 quarters. The position peaked at $1.04M in Q4 2017. 73 funds tracked by Wall St. Rank hold XPH as of Q2 2020.

Oliver Luxxe Assets reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q2 2020 after selling out during the quarter.
Oliver Luxxe Assets sold 5,820 State Street SPDR S&P Pharmaceuticals ETF shares in Q2 2020, an estimated $218K.
Oliver Luxxe Assets first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q3 2017 and held it in 9 quarters.
Oliver Luxxe Assets's State Street SPDR S&P Pharmaceuticals ETF position peaked at $1.04M in Q4 2017.
73 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q2 2020.

Based on Oliver Luxxe Assets's 13F filing for Q2 2020, filed 12 Aug 2020.